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Colorectal cancer (CRC) is the fourth leading cause of cancer related death worldwide due to high apoptotic resistance and
metastatic potential. Because mutations as well as deregulation of CK1 isoforms contribute to tumor development and tumor
progression, CK1 has become an interesting drug target. In this study we show that CK1 isoforms are differently expressed in
colon tumor cell lines and that growth of these cell lines can be inhibited by CK1-specific inhibitors. Furthermore, expression
of CK1d and E is changed in colorectal tumors compared to normal bowel epithelium, and high CK1E expression levels signifi-
cantly correlate with prolonged patients’ survival. In addition to changes in CK1d and E expression, mutations within exon 3
of CK1d were detected in colorectal tumors. These mutations influence ATP binding resulting in changes in kinetic parameters
of CK1d. Overexpression of these mutants in HT29 cells alters their ability to grow anchorage independently. Consistent with
these results, these CK1d mutants lead to differences in proliferation rate and tumor size in xenografts due to changes in
gene expression, especially in genes involved in regulation of cell proliferation, cell cycle, and apoptosis. In summary, our
results provide evidence that changes in the expression levels of CK1 isoforms in colorectal tumors correlate with patients’
survival. Furthermore, CK1 mutants affect growth and proliferation of tumor cells and induce tumor growth in xenografts, lead-
ing to the assumption that CK1 isoforms provide interesting targets for the development of novel effective therapeutic con-
cepts to treat colorectal cancer.
Colorectal cancer (CRC) is the third most common cancer
and the fourth leading cause of cancer related death in both
men and women worldwide.1,2 Since the 5-year survival rate
of metastatic CRC is only about 10%, it is important to
receive detailed information on molecular level regarding its
carcinogenesis and progression and to search for new effec-
tive therapy concepts. Although modern treatment schemes
have resulted in prolonged median survival of patients, the
overall prognosis is still poor. Because of high apoptotic
resistance and metastatic potential conventional chemothera-
peutic concepts are often ineffective in the treatment of CRC,
or are associated with severe side effects. Therefore, research
efforts are currently focusing on the identiﬁcation of novel
target molecules. In line with this notion, drug discovery
projects aiming to develop effective and isoform-speciﬁc CK1
inhibitors have drawn considerable interest. Members of the
serine/threonine-speciﬁc CK1 family are evolutionary highly
conserved and ubiquitously expressed in eukaryotic organ-
isms. So far, seven distinct genes encoding mammalian CK1
isoforms a, b, g1, g2, g3, d, E and various splice variants
have been characterized. CK1 isoforms play major regulatory
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roles in almost all cellular processes including proliferation,
apoptosis, and cell differentiation. As a consequence of cellu-
lar stress conditions, CK1 is able to alter the activity of key
regulatory proteins and signal integration molecules and is
tightly connected to the regulation of b-catenin-, p53- and
MDM2-speciﬁc functions and degradation. Considering the
importance of CK1 in regulating tumor suppressor functions
as well as the contribution of CK1 family members in path-
ways associated with growth, development, and homeostasis,
like Wnt, Hedgehog and Hippo signaling pathways, it is not
surprising that mutations and alterations in the expression
and/or activity of CK1 isoforms are often detected in various
tumor entities.3 Furthermore, CK1d expression and activity is
elevated in crypts in a murine colonic hyperplasia model.4 In
this context a CK1d point mutation (R324H) identiﬁed in a
patient with large and multiple polyps has been correlated
with a signiﬁcantly increased oncogenic potential.5 However,
so far the role of CK1 isoforms in CRC development and
progression as well as their potential as valid drug targets in
the treatment of CRC has not been addressed in detail.
In this study, we report on human colon tumor cell lines
exhibiting differences in the expression and activity levels of
CK1 isoforms. Herein, inhibition of CK1d and E by novel
CK1-speciﬁc inhibitors is shown to block tumor cell prolifer-
ation. Furthermore, we show that CK1d and E expression is
changed in colorectal tumors and that high CK1E expression
levels signiﬁcantly correlate with prolonged survival. Muta-
tions in CK1d exon 3 were detected in colorectal tumors
leading to altered kinetic parameters when being introduced
into recombinant CK1d fusion proteins. Overexpression of
these mutants in HT29 cells alters cell proliferation and the
ability of cells to grow anchorage independently. Consistent
with these results, CK1d mutations lead to differences in pro-
liferation rate and tumor size in a mouse xenotransplantation
model. Finally, gene expression analyses revealed changes in
genes involved in regulation of cell death, cell cycle, cell pro-
liferation, and cytoskeleton organization.
Material and Methods
Human colorectal tissue
In summary 122 patients suffering from CRC whose
informed consent was obtained prior to surgery were chosen.
The specimens included normal large bowel epithelia and
tumor tissue of different grades (G). Formalin-ﬁxed parafﬁn-
embedded sections were used for immunohistochemical stud-
ies. The project was performed with the permission of the
independent local ethics committee of the University of Ulm
(approval 268/2008).
Immunohistochemistry
Staining of CK1d, CK1E and Ki-67 in deparafﬁnized and
rehydrated tissue sections was performed as described previ-
ously.6 Sections were graded with regard to intensity of the
CK1d- and E-speciﬁc staining. Intensity levels of the CK1d-
and E-speciﬁc staining were graded as2 negative (no stai-
ning),1 (weak intensity of staining), 11 (moderate inten-
sity), or 111 (strong intensity) by two independent
observers (expert pathologists).
Mutational analysis
RNA was isolated from HT29 cells and transcribed into
cDNA using Transcriptor First Strand cDNA Synthesis kit
(Roche Diagnostics, Mannheim, Germany). Genomic DNA
was puriﬁed from colon tissue samples using the MasterPure
Complete DNA and RNA Puriﬁcation Kit (EPICENTRE Bio-
technologies, Madison, USA) according to the manufacturer’s
protocol. CK1d and exon 3 of CK1d were ampliﬁed by PCR
using intron-speciﬁc primers: CK1d_fw: 50-GGATCCATGGA
GCTGAGAGTCGGGAACAG-30, CK1d_rv: 50-GGATCCTCA
TCGGTGCACGACAGACTGA-30, CK1dexon3_fw: 50-AGCT
GAGGCAGGGCCTGGAC-30, CK1dexon3_rv: 50-CAGCACA
AGCGAGTGGCTGA-30. The resulting PCR products were
sequenced by GATC-Biotech AG (Konstanz, Germany).
Sequencing results were analyzed by using BLAST. Nucleo-
tide and amino acid sequences were aligned with the NCBI
database sequences for CK1d on DNA (NM_139062.1) and
protein level (NP_620693.1).
Molecular modeling
Molecular modeling was performed on a DELL T5500 work-
station (DELL, Round Rock, USA) using Schr€odinger Suite
Maestro 9.7.013 (Schr€odinger, Portland USA, 2014). A
human CK1d model was generated based on the high resolu-
tion structure PDB 3UZP (resolution5 1.94 Å) using the
protein preparation wizard (standard settings). By using this
wtCK1d apo-structure we next docked Mg-ATP into the
ATP binding pocket (wtCK1d, Fig. 5a) in order to represent
an active conformation of the kinase domain. Subsequently,
What’s new?
Mutations and alterations in the expression and activity of CK1 isoforms--which play important roles in many cellular
processes--are known to contribute to tumorigenesis and tumor progression. The authors show that expression of CK1E corre-
lates with the survival of colorectal cancer patients. Furthermore, they identify CK1d mutations leading to altered kinetic
parameters in vitro and, when introduced into a carcinoma cell line, altered tumor growth in vivo. Since the mutant with high
oncogenic potential also displays greater sensitivity to CK1-specific inhibitors, the findings underline the potential use of
CK1-specific inhibitors in the treatment of colorectal cancer and personalized medicine.
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the following mutations were modeled by changing the side
chains of amino acids: 67 (Tyr!Ser) (mutCK1dT67S, Fig. 5b),
68 (Ile!Asn) (mutCK1dI68N, Fig. 5c), 66 (Pro!Thr) and 69
(Agr!Lys) simultaneously (mutCK1dP66T,R69K, Fig. 5d). All
mutated systems were minimized using OPLS2.1 force ﬁeld
by default settings implemented in the Schr€odinger software
package. The role of those residues toward the binding of
ATP was then analyzed by comparing molecular details of
the wtCK1d structure with the mutated systems, respectively.
Cloning of expression vectors
Human CK1dTV2 was ampliﬁed by PCR using the primers
CK1dTV2_fw: 50-GGATCCATGCATCACCATCACCATCAC
CCCGGGATGGAGCTGAGAGTCGGGAAC-30 and CK1dV
T2_rv 50-GGATCCCTACTTGCCGTGGTGTTCGAAA-30.
The resulting PCR product was ligated into pcDNA3.1/V5-His
TOPO TA (Invitrogen, Karlsruhe, Germany) or pGEX6P-3 (GE
Healthcare, Munich, Germany) expression vectors. To intro-
duce the mutational changes obtained from mutational analysis
following primers were used for site directed mutagenesis:
mtCK1dP66TR69K_fw: 50-GAGTGGGCATCACCACCAT-
CAAATGGTGCGGG-30, mtCK1dP66TR69K_rv: 50-CCCGCA
CCATTTGATGGTGGTGATGCCCACTC-30, mtCK1dT67S_
fw: 50-GAGTGGGCATCCCCAGCATCAGATGGTGCG-30,
mtCK1dT67S_rv: 50-CGCACCATCTGATGCTGGGGATGCC
CACTC-30, mtCK1dI68N_fw: 50-GTGGGCATCCCCACCAA-
CAGATGGTGCGG-30, mtCK1dI68N_rv: 50-CCGCACCATC
TGTTGGTGGGGATGCCCAC-30
Expression and purification of recombinant proteins
GST fusion proteins GST-p531–64 (FP267),7 GST-wtCK1d
(FP449),7 GST-b-catenin12181 (FP1355),8 as well as the dif-
ferent GST–mtCK1d (T67S; I68N; P66T,R69K) were
expressed and puriﬁed as described previously.9
In vitro kinase assay
In vitro kinase assays were performed as described elsewhere.8
Where indicated, the CK1d- and E-speciﬁc inhibitors IC261,10
D4476,11 compound P17,12 as well as the diﬂuoro-dioxolo-
benzoimidazole derived compounds 1 and 2 (derivatives of
compound 513) were used in given concentrations. Either
human recombinant CK1d kinase domain (CK1dkd) (NEB,
Frankfurt am Main, Germany), CK1E (Invitrogen, Karlsruhe,
Germany), full length rat GST-wtCK1d (FP449), human GST-
wtCK1d and human GST-mtCK1d (T67S; I68N; P66T,R69K;)
or each single fraction of fractionated HT29, SW620 or
SW480 cellular extracts were used as sources of enzyme. GST-
p531–64 (FP267)7 and GST-b-catenin1–181 (FP1355)8 served as
substrates. Michaelis–Menten kinetics were performed using
increasing concentrations of substrate while maintaining con-
stant concentrations of ATP (10 mM) and kinase.
Western blot analysis
Western blot analyses were performed as described previ-
ously.6 Following primary antibodies were used: anti-CK1a
(1:250), anti-CK1d (1:250) (both SantaCruz Biotechnology,
Heidelberg, Germany), anti-CK1E (1:300) (BD Bioscience,
Heidelberg, Germany), anti-b-actin (1:10,000) (Sigma–
Aldrich, Steinheim, Germany), and anti-His-tags (1:1,000)
(Cell Signaling, Leiden, Netherlands). Immunocomplexes
were detected using peroxidase-conjugated anti-mouse
(1:10,000), anti-rabbit IgG (1:2,000) (both GE Healthcare,
Munich, Germany) or anti-goat IgG (1:2,500) (Rockland
Immunochemicals, Gilbertsville, USA) followed by chemilu-
minescence detection (ECL; GE Healthcare, Munich, Ger-
many). For quantitative analysis, the intensity of the protein
bands was analyzed using TINA software (Raytest Iso-
topenmessger€ate, Straubenhardt, Germany).
Fractionation of cellular extracts
About 3 mg of total protein of cellular extracts was applied
to an anion exchange column (Resource Q) attached to an
EttanLC puriﬁer (GE Healthcare, Munich, Germany) as
described earlier.8
Cell lines and stable transfection
Human colon tumor cell lines HT29,14 SW620 and SW480,15
obtained from the American Type Culture Collection (Mana-
ssas, VA), were maintained in McCoy’s 5A (HT29) or Leibo-
vitz’s L-15 (SW620 and SW480) medium, supplemented with
10 % heat-inactivated fetal calf serum (Gibco BRL, Karlsruhe,
Germany), L-glutamine (2 mM), 100 U ml21 penicillin and
100 mg ml21 streptomycin. For transfection Xfect Transfec-
tion Reagent (Clontech, Heidelberg, Germany) was used
according to the manufacturer’s instructions. Selected clones
of transfected cells were cultured under selective growth con-
ditions with 750 mg ml21 G418.
Cell viability analysis
The cytotoxic effects of IC261,10 and compounds 1 and 2
were determined by conventional MTT assay using a standard
protocol described previously.16 Results obtained from MTT
assays of treated HT29, SW480 and SW620 cells were normal-
ized and GraphPad Prism 6 software (Graph-Pad Software,
San Diego, CA) was used to generate graphs for cell survival.
Cell cycle analysis
FACS analysis of SW620, SW480, and HT29 cells either
untreated or treated with different concentrations of IC261
and compounds 1 and 2 for 48 hr were performed as
described previously.13
Soft agar assay
The 2 3 104 HT29 cells stably transfected with the empty
vector or the different mutant CK1d bearing plasmids were
seeded in soft agar as described previously.17
In vivo tumorigenicity assay
Mice were housed and handled in accordance to ofﬁcial regula-
tions for care and use of laboratory animals (UKCCCR
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Guidelines for the Welfare of Animals in Experimental Neopla-
sia). Ethical approval of the animal experiments was granted
by the Regierungspr€asidium T€ubingen (permission number
1042). 5 3 106 cells of HT29 cells stably expressing vector
alone or different CK1d point mutations were injected subcuta-
neously into the dorsolateral sites of female 6- to 8-week-old
BALB/C athymic mice (Athymic Nude-Foxn1nu; Harlan, Madi-
son, WI). Animals were regularly monitored for tumor forma-
tion and were sacriﬁced by asphyxiation with CO2 27 days
after injection. Tumors were excised, measured, weighed and
ﬁxed in formalin or shock frozen in liquid nitrogen.
Microarray analysis
Total RNA was isolated using the RNeasy Mini Kit (Qiagen,
Hilden, Germany). Microarray analyses were performed on
Gene 1.0 ST GeneChip arrays (Affymetrix, Santa Clara, CA).
Chips were scanned with an Affymetrix GeneChip Scanner
3000 and images were analyzed subsequently using AffymetrixVR
Expression ConsoleTM Software in combination with BRB-
ArrayTools (http://linus.nci.nih.gov/BRB-ArrayTools.html). Raw
feature data were normalized using RMA normalization.18
Class comparison. We identiﬁed differentially expressed
genes among the two classes using a two sample t test. Genes
were considered signiﬁcant if their p value was <0.05 and
displayed a fold change between the two groups of at least
1.5-fold. We used the multivariate permutation test to pro-
vide 90% conﬁdence that the false discovery rate was <10%.
The test statistics used are random variance t-statistics for
each gene.19 Although t-statistics were used, the multivariate
permutation test is non-parametric and does not require the
assumption of Gaussian distributions.
Gene ontology. To identify the most affected biological proc-
esses, as deﬁned by Gene Ontology annotation, we used the
GoMINER analysis tool.20 Complete microarray data are available
at Gene Expression Omnibus (accession number: GSE57840).
Statistical analysis
Experiments were performed in triplicates. Data are pre-
sented as mean6 SEM. Statistical differences were performed
with the GraphPad Prism 6 software (Graph-Pad Software
Inc., San Diego, CA). For the analysis of the patients’ survival
Kaplan-Meier curves were compared using the log-rank test.
CK1E expression patterns and correlations of CK1E and clini-
copathologic parameters were examined by chi-squared test.
All statistical calculations were performed using SPSS, Ver-
sion 20 (SPSS, Chicago, IL). Signiﬁcance of changes was
assessed by the application of an unpaired t-test, with p val-
ues< 0.05 considered to be statistically signiﬁcant.
Results
Expression and activity levels of CK1 isoforms differ in
colon tumor cell lines
Alterations in the expression and/or activity levels of CK1 iso-
forms, especially of CK1d and E, contribute to changes in sig-
nal transduction pathways leading to apoptosis resistance of
tumor cells.6,21–23 Thus, analysis of CK1a, d and E in human
colon tumor cell lines revealed no differences in the expres-
sion of CK1E in SW480, SW620 and HT29 cells, whereas the
expression levels of CK1d and a differ (Figs. 1a and 1b). Fur-
thermore, high CK1d/E kinase activity was detected in kinase
peak fractions of fractionated extracts of SW620 and SW480
cells whereas the kinase activity in the kinase peak fractions
of fractionated HT29 extracts was reduced three-fold (Fig. 1c).
The kinase peak activity could be conﬁrmed to be mainly due
to the activity of CK1d/E since treatment with the CK1d/E-
speciﬁc ATP competitive inhibitors D4476, IC261 and P17, a
2-acylaminopyridine-4-yl-imidazole derivative12 decreased
kinase activity up to 70% (Fig. 1d).
CK1-specific inhibitors suppress the growth of colon tumor
cell lines
CK1-speciﬁc inhibitors are able to inhibit the growth of
tumor cells either inducing cell cycle arrest or apoptosis in a
cell line and dose-dependent manner.6,10,13,24 Therefore, the
ability of IC261 and two newly developed CK1d-speciﬁc
diﬂuoro-dioxolo-benzoimidazole derivatives, namely com-
pounds 1 and 225 were used to inhibit the growth of various
colon tumor cell lines. At a concentration of 1 mM all three
inhibitors suppressed proliferation of SW480, SW620 and
HT29 cells (Fig. 2a). Determination of EC50 values revealed
that compound 2 exhibits the most potent inhibitory effects
towards all tested cell lines (Supporting Information Table
S2). FACS analyses furthermore revealed cell line speciﬁcity
and dose-dependent differences in the effects of these inhibi-
tors. Treatment with IC261 predominantly resulted in an
increase of dead cells whereas application of both 1 and 2
increased the amount of G2 arrested cells (Fig. 2b). As
already described earlier26,27 formation of polyploidy (up to
20%) in SW480 and SW620 cells after treatment with 0.8 mM
IC261 could also be observed. In contrast, treatment of these
cells with either 0.6 mM of compound 2 or 4.5 mM of com-
pound 1 induced polyploidy to a much lesser extent (<3% of
cells in total).
Expression of CK1d and E is changed in colorectal tumor
tissue
Because CK1d/E-speciﬁc inhibitors affect growth of various
colon tumor cell lines their use in novel therapeutic concepts
should be considered. This applies in particular to colorectal
tumor tissue if alterations in the expression of CK1d and E,
which share 98% homology within their kinase domains,
could be detected. Immunohistochemical analyses of CK1d
and E expression levels in tissue specimens of our CRC
cohort revealed a cytoplasmic staining of CK1d and E in nor-
mal colorectal epithelium, adenomas, and invasive carcino-
mas (Fig. 3). In normal mucosa, CK1d and E expression
tended to be most pronounced in the apical part of the colo-
nocytes (Figs. 3a and 3b). Staining of low grade adenomas
essentially recapitulated the situation in normal epithelium
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(Figs. 3c and 3d), whereas in high grade adenomas and inva-
sive carcinomas a diffuse expression of different intensity was
observed (Figs. 3e23j).
High CK1E expression levels predict better survival rates
of CRC patients
Next, we correlated the expression levels of CK1d and E in
tumors of 122 CRC patients, whose clinicopathological param-
eters and overall survival rates are summarized in Supporting
Information Tables S1a–S1c and Figure S1. Our results clearly
demonstrate that in the cohort of 122 CRC patients higher
CK1E expression in tumors (both RNA and protein level) cor-
relates with prolonged survival rates (p5 0.28 and p5 0.03,
respectively). Even more strikingly, this is the case in patients
with grade 2 tumors (p5 0.01 and p5 0.02, respectively, Fig.
4). In contrast, no signiﬁcant correlation between CK1d
expression (RNA and protein level) and overall survival of
patients could be observed (data not shown).
Mutations within exon 3 of CK1d lead to altered kinase
activity and catalytic efficiency
Increased oncogenic potential has been reported for a CK1d
mutant identiﬁed in a patient with large and multiple colonic
polyps5 and CK1d expression and activity is elevated in crypts
in a murine colonic hyperplasia model.4 Hence, detailed analysis
of CK1d became more relevant since several amino acids within
exon 3 seem to inﬂuence binding of ATP into the ATP pocket
and mediate the interaction and selectivity of CK1d-speciﬁc
inhibitors.28 Therefore, mutations in exon 3 encoded amino
acids could affect CK1 activity itself as well as modulate the
binding of CK1d-speciﬁc inhibitors. To investigate this hypothe-
sis we sequenced CK1d exon 3 from genomic DNA of 60 CRC
patients. Our data revealed a noticeable accumulation of point
mutations between amino acids 66 and 69 in three patients,
resulting in amino acid exchanges of amino acids 67 (T67S), 68
(I68N), as well as 66 and 69 (P66T, R69K). To analyze the
molecular role of these mutations in more detail, molecular
modeling was performed to generate homology models of
mtCK1dT67S, mtCK1dI68N, and the double mutant
mtCK1dP66T,R69K (Figs. 5a–5d). Within these CK1d models all
mutations were found to be situated in a single rear loop in close
proximity to the hinge region of the ATP binding pocket, indi-
cating an indirect structural impact toward amino acids directly
involved in ATP binding. In detail, due to the slightly smaller
serine (versus threonine) residue mtCK1dT67S appears to be
more ﬂexible in terms of ATP binding which increases the
Figure 1. Expression and activity levels of CK1 isoforms differ in various colon tumor cell lines. (a) Western blot analysis revealed no differ-
ences in the expression of CK1E in SW480, SW620, and HT29 cells. However, expression of CK1a and d showed stronger cell line-specific
differences. (b) Quantification of the expression levels revealed a reduction of CK1d in SW620 and HT29 cells by 20 and 70%, respectively
and a reduction of CK1a levels in SW620 and SW480 cells by 25 and 45 %, respectively, compared to HT29 cells. (c) Analysis of CK1d and
E activity in fractionated extracts from colon tumor cells revealed a three-fold reduction in HT29 cells compared to CK1d/E activity detected
in SW620 and SW480 cells. (d) CK1d/E-specific inhibitors inhibit the kinase activity present in the kinase peak fractions of B2 and B4 of
all tested cell lines, thereby confirming that the kinase peak activity is mainly due to the activity of CK1d and E.
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catalytic activity of the kinase. In case of mtCK1dI68N the polar
side chain of asparagine is able to build additional H-bonds to
the hinge region towards the gatekeeper residue Met82. In con-
trast, mtCK1dP66T,R69K bears more polar and less rigid side
chains (in comparison to wtCK1d) disturbing the hinge region
so that mtCK1dP66T,R69K is supposed to be catalytically less
active. To test this hypothesis, we compared the kinetic parame-
ters of the different CK1d mutants with those of wtCK1d. Our
results indicate signiﬁcant differences regarding the molecular
activity (kcat) and the catalytic efﬁciency (kcat/Km) of the CK1d
mutants depending on their substrates (Figs. 5e and 5f). Com-
pared to GST-mtCK1dI68N and GST–mtCK1dP66T,R69K, GST-
mtCK1dT67S shows signiﬁcantly higher activity and efﬁciency
levels (all p values< 0.05) in phosphorylating GST-p531–64 and
GST-b–catenin.1–181 Additionally, treatment of GST-wtCK1d
and GST-mtCK1dT67S with the CK1d-speciﬁc inhibitor com-
pounds 1 and 2 leads to an increased inhibition of GST-
mtCK1dT67S compared to GST-wtCK1d, indicated by the deter-
mined IC50 values (Fig. 5g and Supporting Information Table S3).
Expression of CK1d mutants in HT29 cells leads to
changes in number of colonies in soft agar
Next we investigated the oncogenic potential of the identiﬁed
CK1d mutants using the colony formation assay. The differ-
ent CK1d mutant expressing plasmids as well as the empty
vector were stably introduced into the genome of wtCK1d
expressing HT29 cells. Clones were chosen according to equal
expression of exogenous CK1d (Supporting Information Fig.
S2). Compared to parental HT29 cells and HT29 cells
expressing the vector control, HT29 cells stably expressing
mtCK1dT67S are able to form an increased number of colo-
nies in soft agar. In contrast, mtCK1dI68N and
mtCK1dP66T,R69K expressing HT29 cells form a reduced
Figure 2. CK1-specific inhibitors IC261, compound 1, and compound 2 suppress the growth of colon tumor cell lines. (a) Cancer cell growth
of HT29, SW480 and SW620 cells is reduced after inhibitor treatment. Graphs for IC261 and compound 2 are overlapping. Filled circles:
control (DMSO treated), open circles: IC261 treated, filled triangles: compound 1 treated, open triangles: compound 2 treated. (b) Cell cycle
determination of colon tumor cell lines treated with different concentrations of IC261, compound 1 or compound 2 after 48 hr. IC261 treat-
ment predominantly resulted in an increase of dead cells, whereas application of compound 1 and 2 increased the amount of G2 arrested
cells. Furthermore, high concentrations of IC261 obviously induced the formation of polyploidy in SW480 and SW620 cells.
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number of colonies in soft agar compared to vector control
and mtCK1dT67S expressing HT29 cells (Fig. 5h).
CK1d mutations lead to differences in tumor size in a
xenotransplantation model
So far, our results strongly suggest that mtCK1dT67S shows
increased oncogenic potential. To analyze the effects of the
different exon 3 mutants of CK1d on tumor cell growth and
proliferation in vivo, we generated xenografts. Mice injected
with HT29 cells expressing mtCK1dT67S developed signiﬁ-
cantly larger tumors than those mice injected with cells
expressing vector control, mtCK1dI68N, or mtCK1dP66T,R69K
(p5 0.002, p5 0.011 and p5 0.004, respectively; Figs. 6a and
6b). Increased proliferation rates of tumors induced by
mtCK1dT67S expressing HT29 cells were matched to enhanced
tumor cell proliferation, as demonstrated by immunohisto-
chemical staining for (Fig. 6c). Microarray analysis was per-
formed to detect changes in gene expression in the different
groups (vector control group (ctrl.), mtCK1dT67S, mtCK1dI68N
and mtCK1dP66T,R69K). The most differentially expressed genes
for the three contrasts mtCK1dT67S versus ctrl., mtCK1dI68N
versus ctrl., and mtCK1dP66T,R69K versus ctrl. are shown in
Supporting Information Figure S3 and Table S4. Comparison
of genes expressed by mtCK1dT67S and mtCK1dP66T,R69K
results in the identiﬁcation of 57 genes differentially expressed
between the two groups. Some of these genes play roles in
regulation of various cellular processes like cell proliferation
(CXCL10, LAMP3, GPC3), cell death (XAF1, IFIT2, WFS1),
cell cycle (TGFB2, PSMB9), and cytoskeleton organization
(DPYSL, LYN). Genes displaying strongest differential expres-
sion were CLEC3A, SLCO1B3, SLC14A1, CDH17, CKMT1A,
and TRIM22 (Fig. 6d). Furthermore, we found variations in
the expression levels of genes involved in Wnt, Hedgehog,
and Hippo signaling like FZD3, DKK1, PRKACB and HIPK2
(Supporting Information Fig. S4).
Discussion
Members of the CK1 family play major regulatory roles in
various cellular processes. Considering the importance of
CK1 isoforms for precise cell division and regulation of
tumor suppressor functions it is not surprising that muta-
tions as well as changes in their expression levels and/or
activity are found in various tumor entities, including breast
cancer, adenocarcinomas of the pancreas, and ovarian can-
cer.3 However, the signiﬁcance of CK1 isoforms in CRC and
their therapeutic potential have not yet been addressed in
detail.
In the present work we detected differences in the expres-
sion levels and activity of CK1a, d and E in colon cancer cell
lines SW620, SW480 and HT29. Furthermore, we could show
that growth rates of all three colon tumor cell lines were sig-
niﬁcantly reduced in the presence of the CK1d/E-speciﬁc
inhibitors IC261, compound 1, and compound 2.25 The two
novel CK1d-speciﬁc inhibitors 1 and 2 which are related to
previously published CK1d and E selective benzimidazole
derivatives13 strongly inhibited the growth of all three colon
tumor cell lines. Furthermore, cell viability and cell cycle dis-
tribution in a cell line and dose-dependent manner were
affected pointing to an essential role for CK1d in cancer cell
proliferation. Our data show that CK1d/E inhibitors are able
to inﬂuence tumor cell kinetics by different mechanisms.
While IC261 predominantly induced cell death in HT29 and
SW480 cells treatment of SW620 cells resulted in a G2 arrest.
In contrast, compounds 1 and 2 mainly induced a G2/M
arrest in all analyzed colon tumor cell lines. In other model
systems, IC261 has been described as a CK1d- and E-speciﬁc
inhibitor, which suppressed the growth of pancreatic tumor
cell lines and tumor xenografts.6,10 These observations and
our own data are in line with previous ﬁndings that the
effects of CK1-speciﬁc inhibitors are dependent on the cellu-
lar background and can lead to G2/M arrest or
Figure 3. Expression of CK1d and E is changed in colorectal tumor tissues. Representative pictures of immunohistochemically stained cross-
sections and tissue sections from CRC patients are shown. CK1d and E expression tended to be most pronounced in the apical part of the
colonocytes in normal colon tissues (a, b), weakly positive in periphery of goblet cells in low grade adenomas (c, d), and positive and diffused
in high grade adenomas (e, f). Strong diffused staining of different intensities of CK1d and E was observed in invasive carcinomas (g–j).
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apoptosis.6,26,27,29 In addition, it has to be considered that
IC261 may also affect cell division through direct binding to
the microtubule apparatus.21,30 Therefore, IC261 inhibition
data should always be interpreted with caution. In contrast,
off-target effects have so far not been described for com-
pounds 1 and 2. Hence, it can be assumed that their inhibi-
tion of cell proliferation is caused by 1 and 2 potently
blocking CK1d. Therefore, CK1d inhibition may be regarded
as a potential therapeutic concept for the treatment of CRC,
especially if CK1d is overexpressed in tumors. Whereas the
CK1d and E immunoreactivity was not altered in low grade
adenomas compared to normal tissue, expression levels of
CK1d and E varied markedly in high grade adenomas and
invasive carcinomas. However, in the present study we could
not detect any correlation between the expression levels of
CK1d and E and tumor grade, although several studies report
such correlation in other tumor entities.6,17,31,32 Nevertheless,
our data clearly show that high expression levels of CK1E sig-
niﬁcantly correlate with survival of the cohort of 122 CRC
patients and especially of patients with grade 2 tumors. Until
now, several studies have indicated that CK1E plays a signiﬁ-
cant role in human cancers and is expressed in various tumor
entities.3 Our results are consistent with the data of Lin and
coworkers, who recently demonstrated that CK1E expression
in oral cancer is related to considerably better overall survival
compared to patients with CK1E negative tumors.33 Contra-
rily, Rodriguez and coworkers showed that overexpression of
CK1E in ovarian cancer is associated with poor survival,34
strengthening the hypothesis that the role of CK1E in carci-
nogenesis varies in different cancer entities.
Mutations within the coding region of CK1d can inﬂuence
both ATP and substrate binding thereby altering the onco-
genic potential of CK1d.3 Our mutational analysis of exon 3
of CK1d is based on the fact that mutations of exon 3
Figure 4. Kaplan–Meier survival curves of grading independent and grade 2 CRC patients reveal better survival rates in patients with high
CK1E expression levels. (a) Patients in the grading independent group with tumors expressing high CK1E RNA levels (RQ>1) tended to a
higher survival rate (p50.28). (b) In the subgroup of patients with grade 2 tumors high CK1E RNA expression levels significantly correlate
with prolonged survival (p50.01). (c, d) On protein level, patients with high CK1E protein levels (11/111) had a significantly (p50.03
and p50.02, respectively) higher overall survival than patients with low CK1E protein levels (1) in grading independent group and grade 2
subgroup, respectively. Tick marks on the curve indicate censored subjects.
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encoded amino acids can affect kinase activity as well as the
effects of CK1d-speciﬁc inhibitors.28 We identiﬁed several
point mutations in a single rear loop in close proximity to
the hinge region of the ATP binding pocket. These mutations
lead to altered kinase activity and efﬁciency in phosphoryl-
ating different CK1d substrates by a potential structural
impact towards amino acids directly involved in ATP bind-
ing. The kinetic parameters of the different CK1d point
mutants conﬁrmed our hypothesis of increased catalytic
activity and efﬁciency of mtCK1dT67S due to the smaller
Figure 5. Mutations within exon 3 of CK1d lead to altered biochemical properties in vitro and differences in anchorage independent cell
growth. Homology models of wtCK1d (a) and details of mutant structures of mtCK1dT67S (b), mtCK1dI68N (c) and mtCK1dP66T,R69K (d) illustrat-
ing the position of these mutations in the protein. (e, f) Mutations in exon 3 of CK1d exhibit significant differences in enzyme activity and
efficiency to phosphorylate different substrate proteins in vitro. mtCK1dT67S shows highest activity and efficiency in phosphorylating GST-
p531–64 and GST-b–catenin1–181 compared to wtCK1d, mtCK1dI68N and mtCK1dP66T,R69K. (g) GST-mtCK1dT67S shows increased sensitivity
towards treatment with compound 1 and 2 compared to GST-wtCK1d. (h) Colony formation assays indicate high oncogenic potential of
HT29 cells expressing mtCK1dT67S which show an increased number of colonies in soft agar compared to wtCK1d control, mtCK1dI68N or
mtCK1dP66T,R69K expressing HT29 cells, respectively.
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serine (versus threonine) residue leading to more ﬂexibility in
terms of ATP binding and increased sensitivity towards the
treatment with the ATP competitive CK1d-speciﬁc inhibitors
1 and 2. Consistent with the biochemical properties
mtCK1dT67S expressing HT29 cells exhibited a higher onco-
genic potential as wtCK1d expressing HT29 cells indicated by
their enhanced ability to grow anchorage independently. Sim-
ilarly, subcutaneous injection of mtCK1dT67S expressing
HT29 cells in nude mice resulted in the formation of highly
proliferating and fast growing tumors underlining the high
oncogenic potential of mtCK1dT67S. In contrast,
mtCK1dP66T,R69K showed reduced molecular activity and cat-
alytical efﬁciency as well as reduced tumor growth in vivo,
which can be explained by its more polar and less rigid side
Figure 6. CK1d mutations lead to differences in tumor size, proliferation rate, and gene expression in vivo. (a, b) Tumors induced by
mtCK1dT67S overexpressing HT29 cells exhibit significantly larger tumor volumes compared to those induced by wtCK1d control, mtCK1dI68N
and mtCK1dP66T,R69K expressing cells. (c) Immunohistochemical analyses of tumor sections from the wtCK1d control, mtCK1dT67S,
mtCK1dI68N and mtCK1dP66T,R69K groups revealed an increased proliferation rate indicated by Ki-67 staining in mtCK1dT67S induced tumors
compared to that in wtCK1d control, mtCK1dI68N and mtCK1dP66T,R69K induced tumors. Ki-67-positive tumor cells were detected with a range
from 13 to 332 per 50 high power fields (HPF) in the respective group. (d) Heat map showing the most differentially expressed genes
defined by a> threefold change and p<0.05 for the contrast mtCK1dP66T,R69K versus mtCK1dT67S including 35 genes that where down-
regulated, whereas 22 genes were up-regulated in mtCK1dT67S. Expression values have been color-coded (green decreased; red increased)
and are presented as the fold-change in expression.
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chains (in comparison to wtCK1d) disturbing ﬂexibility of
the hinge region. Although, in case of the CK1dI68N mutant
the polar side chain of asparagine is able to build additional
H-bonds to the hinge region towards the gatekeeper residue
Met 82 thus potentially enhancing the afﬁnity towards ATP,
molecular activity and catalytic efﬁciency is decreased com-
pared to wild type and the CK1dT67S mutant but tumor
growth in vivo is enhanced. These ﬁndings underline the fact
that differences in cellular phenotype and oncogenic potential
induced by different mutants may not only be due to differ-
ences in their catalytic efﬁciency, but due to other properties
like changes of interaction with different partners thereby
activating oncogenic signaling pathways.5,35
Comparison of genes expressed by tumors of mtCK1dT67S
and mtCK1dP66T,R69K transfected cells revealed signiﬁcant dif-
ferences in genes playing roles in various cellular processes
like proliferation, cell death, cell cycle, and cytoskeleton orga-
nization. Genes most strikingly down-regulated in tumors
induced by mtCK1dT67S expressing cells included SLC14A1
and TRIM22, which have already been reported to be
changed in CRC and breast tumors, respectively.36–39 In con-
trast, SLCO1B3 and CDH17 are markedly upregulated in our
ﬁndings. This is in line with ﬁndings from other groups, who
observed a high expression of SLCO1B3 and CDH17 in can-
cer tissues derived from primary and metastatic gastrointesti-
nal tumors.40,41 Furthermore, we found differentially
expressed genes involved in Wnt-, Hedgehog- and Hippo-
signaling, among them FZD3, DKK1, PRKACB and HIPK2.
However, their roles in the development of rapidly proliferat-
ing colorectal tumors remain to be analyzed in more detail in
future experiments.
In conclusion, our study provides evidence that colon tumor
cell lines exhibit differences in expression and activity levels of
CK1d and E. We show that speciﬁc inhibition of these CK1 iso-
forms leads to reduced cell growth, indicating a role of CK1d
and E in tumorigenesis of CRC. For the ﬁrst time, we demon-
strate differences in the expression levels of CK1d and E in
colorectal tumor tissue. Furthermore, we were able to correlate
prolonged patients’ survival with elevated CK1E expression in
colorectal tumor tissue. Contrarily, we identiﬁed a hyperactive
CK1d mutant with increased inhibitor response in vitro as well
as increased growth and proliferation of tumor cells and tumor
growth in vivo, leading to the assumption that CK1 isoforms
provide rewarding targets for new colorectal cancer therapy
concepts. In this regard, it remains challenging to selectively
inhibit CK1d in CRC patients without affecting the activity of
the highly related CK1 isoform E, which seems to contribute to
the observed prolonged survival rate of CRC patients. Therefore,
our study additionally provides evidence that future effort
should concentrate on the development of CK1-speciﬁc inhibi-
tors, either selectively inhibiting a speciﬁc CK1 isoform or CK1
mutants exhibiting an increased oncogenic potential.
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